Market Place
Sourcing Support
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
12 Dec 2023 //
PR NEWSWIRE
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH
11 Dec 2023 //
PRESS RELEASE
Curis Announces Three Presentations at ASH
06 Dec 2023 //
PRESS RELEASE
Curis Enters into Agreement for Emavusertib Combination Study in Melanoma
05 Dec 2023 //
PR NEWSWIRE
Curis Provides Third Quarter 2023 Business Update
02 Nov 2023 //
PRESS RELEASE
FDA lifts partial hold on Curis` PhI/II leukemia study as biotech raises $15M
07 Jul 2023 //
ENDPTS
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Apr 2023 //
PR NEWSWIRE
FDA puts Curis` leukemia trial on partial hold after patient death
04 Apr 2023 //
FIERCE BIOTECH
Curis Provides Fourth Quarter 2022 Business Update
13 Mar 2023 //
PR NEWSWIRE
Curis shrinks headcount by 30% as execs place bigger hopes on blood cancer drug
11 Nov 2022 //
ENDPTS
Curis cuts staff as pending data hint at FDA application
10 Nov 2022 //
FIERCEBIOTECH
Curis Announces Three Presentations at SITC 2022
07 Nov 2022 //
PRNEWSWIRE
FDA lets biotech resume enrollment for part of phase 1/2 leukemia study
31 Aug 2022 //
FIERCEBIOTECH
Curis gets second clinical hold lifted as shares tumble 9%
31 Aug 2022 //
ENDPTS
FDA lifts partial clinical hold on Curis lymphoma study
19 Aug 2022 //
LABIOTECH
Curis Reports Second Quarter 2022 Financial Results and Business Update
04 Aug 2022 //
PRNEWSWIRE
Curis Announces Presentations on Biomarker Development and Emavusertib Data
10 Jun 2022 //
PRNEWSWIRE
Curis Announces Encouraging Emavusertib Data at the 2022 ASCO
04 Jun 2022 //
PRNEWSWIRE
Curis to Present at 2022 Jefferies Global Healthcare Conference
02 Jun 2022 //
PRNEWSWIRE
Curis Announces Abstracts Accepted for Presentation at the EHA 2022
12 May 2022 //
PRNEWSWIRE
Curis Reports First Quarter 2022 Financial Results and Business Update
05 May 2022 //
PRNEWSWIRE
FDA Puts Partial Clinical Hold on Curis` Lymphoma Study of Emavusertib (CA-4948)
11 Apr 2022 //
PRNEWSWIRE
Patient death triggers a second clinical hold for Curis as FDA seeks more data
11 Apr 2022 //
ENDPTS
Curis` lead drug hits roadblock with partial clinical hold after patient death
05 Apr 2022 //
ENDPTS
Curis Reports Fourth Quarter and Year End 2021 Financial Results
24 Feb 2022 //
PRNEWSWIRE
Curis Announces Updated Data in Phase 1/2 Study of CA-4948 Monotherapy and more
06 Jan 2022 //
PRNEWSWIRE
Curis to be Added to Nasdaq Biotechnology Index & iShares Biotechnology ETF
15 Dec 2021 //
PRNEWSWIRE
Curis Reports Third Quarter 2021 Financial Results and Business Update
09 Nov 2021 //
PRNEWSWIRE
Curis Drops; Lower Dose of Leukemia Drug to Reach Phase 2 Study
11 Jun 2021 //
THE STREET
Curis Announces Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy
11 Jun 2021 //
PRNEWSWIRE
Curis Reports First Quarter 2021 Financial Results
12 May 2021 //
PRNEWSWIRE
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML
19 Apr 2021 //
PRNEWSWIRE
Curis Announces Abstract for CA-4948 Accepted for Presentation at the AACR
10 Mar 2021 //
PRNEWSWIRE
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American
10 Mar 2021 //
YAHOO
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination Ibrutinib
09 Feb 2021 //
PRNEWSWIRE
Curis Announces Initiation of Investigator-Sponsored Ph 2 LUCAS CA-4948
02 Feb 2021 //
BIOSPACE
Curis Announces Pricing of Public Offering of Common Stock
09 Dec 2020 //
PRNEWSWIRE
Curis Announces Pricing of Public Offering of Common Stock
08 Dec 2020 //
PRNEWSWIRE
Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948
07 Dec 2020 //
PRNEWSWIRE
Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948
07 Dec 2020 //
PRNEWSWIRE
Curis Announces Collab with the NCI for the DeveP of IRAK4 Inhibitor, CA-4948
10 Nov 2020 //
PRNEWSWIRE
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation
04 Nov 2020 //
PRNEWSWIRE
Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients
07 Jul 2020 //
PRNEWSWIRE
Curis Announces FDA Clearance of IND Application for CI-8993
10 Jun 2020 //
PRNEWSWIRE
Curis, Aurigene announce amendment of collaboration
10 Feb 2020 //
BIOSPECTRUM ASIA
Curis, Aurigene announce amendment of collaboration
10 Feb 2020 //
BIOSPECTRUM ASIA
Curis & Aurigene Announce Amendment of Collaboration CA-170
06 Feb 2020 //
PR NEWSWIRE
